RainDance Appoints Becker Chief Commercial Officer

Wednesday, March 19, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

GUILFORD, Conn., March 18 RainDance Technologies, Inc., adeveloper of NanoReactor droplet-based microfluidic technology, todayannounced the appointment of Stephen E. Becker as Vice President, CommercialOfficer, effective immediately.

"Mr. Becker will be responsible for continuing the growth of the company'scommercial operations as it prepares for the launch of its first life scienceoffering," said Chris McNary, President and Chief Executive Officer, RainDanceTechnologies. "These duties will include the continued development of thesales channels, leading customer service and support programs, and developmentof the strategic marketing plan."

The RainDance platform combines emulsion-based droplets and microfluidicsto enable a host of existing applications in the company's nano-scale format,including genomic analysis, cell-based assays, and single molecule detection.Samples such as cells, nucleic acids, proteins, beads, and chemical compoundsare encapsulated in individual micron-sized droplets on assay-specificmicrofludic chips. Since each droplet is the equivalent of a well in amicrotiter plate, the RainDance platform can process and analyze up to 10,000samples per second with unparalleled accuracy.

Becker joins RainDance from Agilent Technologies, where he served asSenior Sales Manager in the company's Americas Field Operations. There, he ledthe commercial introduction of novel genetic and epigenetic microarray assaysthat achieved over 20% growth rates in 2006 and 2007 in the research andmolecular diagnostics markets. At GE Healthcare (formerly Amersham PharmaciaBiotech), Becker held several senior management assignments, includingDirector, Gene and Protein Discovery, and Director, Business Support. He alsoheld sales management positions at Spectrum Chemical Manufacturing Corporationand Curtin Matheson Scientific, Inc. Becker received a bachelor's degree inbiology from St. Mary's College of California.

"The RainDance droplet technology is a new tool that will allow scientiststo accelerate their research through the advantages provided by nano-scalereactions at unparalleled assay speeds in the life science, diagnostic, andindustrial markets," said McNary. "Mr. Becker's broad experiences will help usdevelop best-in-class commercial processes that support the introduction ofour exciting technology."

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a biomedical technology company devotedto developing and commercializing a proprietary droplet-based microfluidicsplatform. The core of our technology is the generation of stable, nano-litersized droplets that act as the functional equivalent of a test tube, or a wellon a microtiter plate. Each droplet can encapsulate an individual sample ofcells or reagents for both preparative and analytical life science andchemical analysis applications. RainDance recognizes that the rate and scaleof research are accelerating dynamically, and for researchers to keep pacewith these demands, they need the benefits of high-quality individualizedreactions generated on a massive scale. Our vision is to be the worldwideleader in massively parallel sample processing and analytical solutions thatprovide a new standard of data quality.

RainDance has developed instrumentation and disposable microfluidiccircuits that enable researchers to generate experimental results faster thanexisting methodologies, with increased throughput and decreased experimentalvariability. We will provide these tools to academic and commercialresearchers working on a variety of basic and applied research applications.Our proprietary emulsion chemistries and microfluidic manufacturing processallow our platform to miniaturize many biological and chemical assays. Thesesame core attributes will allow the RainDance platform to perform biologicaland chemical applications previously unimaginable or unafford

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store